Edgewise Therapeutics (EWTX) Gains from Investment Securities (2020 - 2026)

Edgewise Therapeutics has reported Gains from Investment Securities over the past 7 years, most recently at $688500.0 for Q1 2026.

  • Quarterly results put Gains from Investment Securities at $688500.0 for Q1 2026, down 86.34% from a year ago — trailing twelve months through Mar 2026 was $688500.0 (down 86.34% YoY), and the annual figure for FY2025 was $1.0 million, down 93.45%.
  • Gains from Investment Securities reached $688500.0 in Q1 2026 per EWTX's latest filing, down from $1.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $15.4 million in Q4 2024 and bottomed at $335248.0 in Q2 2022.
  • Median Gains from Investment Securities over the past 5 years was $2.0 million (2025), compared with a mean of $3.3 million.
  • Peak annual rise in Gains from Investment Securities hit 804.8% in 2025, while the deepest fall reached 93.45% in 2025.
  • Over 5 years, Gains from Investment Securities stood at $2.9 million in 2022, then soared by 70.98% to $5.0 million in 2023, then skyrocketed by 205.89% to $15.4 million in 2024, then tumbled by 93.45% to $1.0 million in 2025, then crashed by 31.81% to $688500.0 in 2026.
  • Business Quant data shows Gains from Investment Securities for EWTX at $688500.0 in Q1 2026, $1.0 million in Q4 2025, and $5.0 million in Q3 2025.